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Abstract
Background: The availability of GABAA receptor binding sites in the brain can be assessed by positron
emission tomography (PET) using the radioligand, [18F]flumazenil. However, the brain uptake and binding
of this PET radioligand are influenced by anesthetic drugs, which are typically needed in preclinical imaging
studies and clinical imaging studies involving patient populations that do not tolerate relatively longer scan
times. The objective of this study was to examine the effects of anesthesia on the binding of [18F]flumazenil
to GABAA receptors in mice.
Methods: Brain and whole blood radioactivity concentrations were measured ex vivo by scintillation counting
or in vivo by PET in four groups of mice following administration of [18F]flumazenil: awake mice and mice
anesthetized with isoflurane, dexmedetomidine, or ketamine/dexmedetomidine. Dynamic PET recordings were
obtained for 60 min in mice anesthetized by either isoflurane or ketamine/dexmedetomidine. Static PET
recordings were obtained at 25 or 55 min after [18F]flumazenil injection in awake or dexmedetomidine-treated
mice acutely anesthetized with isoflurane. The apparent distribution volume (VT*) was calculated for the
hippocampus and frontal cortex from either the full dynamic PET scans using an image-derived input
function or from a series of ex vivo experiments using whole blood as the input function.
Results: PET images showed persistence of high [18F]flumazenil uptake (up to 20 % ID/g) in the brains of
mice scanned under isoflurane or ketamine/dexmedetomidine anesthesia, whereas uptake was almost indiscernible
in late samples or static scans from awake or dexmedetomidine-treated animals. The steady-state VT* was twofold
higher in hippocampus of isoflurane-treated mice and dexmedetomidine-treated mice than in awake mice.
Conclusions: Anesthesia has pronounced effects on the binding and blood-brain distribution of [18F]flumazenil.
Consequently, considerable caution must be exercised in the interpretation of preclinical and clinical PET studies
of GABAA receptors involving the use of anesthesia.
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Background
Type-A γ-aminobutyric acid (GABAA) receptors are the
principal inhibitory neurotransmitter receptors in the
mammalian central nervous system (CNS) [1, 2], and are
an important site of action for anesthetic agents and
sedative drugs. However, there is insufficient information
about the extent of occupancy at GABAA sites affected
by anesthetic agents. GABAA receptors are pentameric
ligand-gated chloride channels, belonging to the Cys-loop
family of receptors [3] and comprised of several different
subunit classes (α1–6, β1–4, γ1–3, δ, ε, π, ρ1–3) [4].
GABA, the endogenous agonist of GABAA receptors,
binds at an orthosteric site located at the interface
between α and β subunits (Fig. 1a) [5, 6] while benzodiaz-
epines (including isoflurane), a clinically important class
of sedatives and anxiolytics, act as positive allosteric
modulators by interacting with a distinct binding site
between the α and γ subunits [4, 6]. A subset of GABAA
receptors containing α4 or α6 subunits are benzodiazepine
insensitive [5]. Many radioligands have been developed for
molecular imaging by positron emission tomography
(PET), which target different sites of the GABAA receptors
([6]). Of these, flumazenil (Ro 15-1788, Fig. 1b), a GABAA
receptor antagonist, has found the widest application in
PET studies. Both [11C]flumazenil and the longer-lived
isotopologue [18F]flumazenil have been used to measure
the in vivo receptor availability in humans [7, 8], monkeys
[9, 10], and rodents [11, 12].
GABAA receptors are very important for cognitive
function [13], and are implicated in the pathologies of
conditions such as anxiety disorders [14, 15], schizophre-
nia [16, 17], and fragile X syndrome [18, 19]. Molecular
imaging studies in humans are typically performed with-
out anesthesia, but sedation may be required in patient
populations who are unable to remain still for the
duration of the scan. Preclinical imaging experiments
in rodents are also commonly carried out under general
anesthesia to minimize animal motion during the scan
[20]. This introduces the possibility of pharmacological
confounds arising from effects of the anesthetic agent on
radioligand binding [21–27]. Selection of an appropriate
anesthetic regimen is especially important for small
animal PET imaging of GABAA receptors, as pharma-
cologically and structurally distinct classes of general
anesthetics (e.g. isoflurane, propofol, and pentobarbital)
are all affecting the GABAA receptor in either direct or
indirect pathways [28]. Anesthesia can therefore poten-
tially confound the results of [11C]flumazenil PET studies
of GABAA receptors in anesthetized humans or animals.
Previous studies have reported that anesthesia with iso-
flurane [29] or propofol [30] increased the distribution
volume (VT) of [
11C]flumazenil in human brain. Further-
more, treatment with the membrane GABA transporter
(GAT1) blocker tiagabine, which increases interstitial
GABA levels, likewise increased the [11C]flumazenil VT in
the human brain [31], suggesting a positive allosteric
potentiation of radioligand binding.
The NMDA-type glutamate receptor antagonist keta-
mine holds promise as a suitable anesthetic for GABAA
receptor PET studies, as subanesthetic ketamine doses
were shown to have minimal effect on [11C]flumazenil
binding in the human brain [32]. Furthermore, ketamine
treatment did not increase interstitial GABA levels in an
MR spectroscopy study in healthy humans [33], however,
more recent studies showed increases in humans with
obsessive compulsive disorder [34] and major depressive
disorder [35]. The α2-adrenergic agonist dexmedetomi-
dine is an anxiolytic agent often used to sedate children
undergoing MRI scans [36]; however, synergistic inter-
actions between α2-adrenergic agonists and benzodi-
azepine binding sites on GABAA receptors have been
described [37]. For example, a pilot study in healthy
humans showed that dexmedetomidine sedation evoked a
slight (4.9–6.0 %) increase in the grey matter binding
potential (BPND) of [
11C]flumazenil [19].
The aim of this study was to explore the effects of the
common anesthetic or sedative agents isoflurane, keta-
mine/dexmedetomidine, and dexmedetomidine alone on
A B
Fig. 1 Structure of [18F]flumazenil (a) and the GABAA receptor with different binding sites (b). The GABA binding site is located at the interface
between α and β subunits while flumazenil and other benzodiazepines act as positive allosteric modulators on a distinct binding site between
the α and γ subunits
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[18F]flumazenil binding to GABAA receptors, in order to
guide the design of pre-clinical and clinical imaging
studies with this radiotracer. We used a combination of
in vivo PET and ex vivo dissection to compare [18F]fluma-
zenil binding in groups of mice with or without anesthesia




All chemicals were from commercial vendors in pharma-
ceutical grade. Production of [18F]flumazenil was based
on the method by Moon et al. [38]. [18F]fluoride in
[18O]water was produced by a medical cyclotron (PET-
trace-18, GE Healthcare) and passed through a PS-HCO3
cartridge, and eluted with a K222/K2CO3 phase transfer
catalyst solution in the chemical module (Tracelab FX-FN,
GE Healthcare). After azeotropic evaporation, 4 mg of
flumazenil diaryliodonium tosylate salt precursor (Bio
Imaging Korea Co., Ltd., Seoul, South Korea) in 1 mL
of DMF with Tempo (1 mg) was added to the reactor.
Fluorination proceeded for 5 min at 150 °C, where-
upon the reaction mixture was diluted with 10 mL of
water and passed twice through a C18 plus cartridge
(Waters). The radiolabeled product was then eluted
from the C18 cartridge with acetonitrile and diluted
with sterile water. The crude solution was purified on
a Luna C18 semi-preparative reversed-phase HPLC
column (Phenomenex, 5 μm, 250 × 10 mm) with a
mobile phase (acetonitrile/water = 20:80) delivered at
5 mL/min. Purified [18F]flumazenil was collected as
the radiochemical peak eluting at 22 min, in a round
bottom flask prefilled with 25 mL water for formulation.
The diluted fraction was passed through the C18 plus
cartridge and rinsed with water. The product was eluted
with 1.5 mL of 100 % USP grade ethanol and diluted by
15 mL of USP grade saline, giving a final concentration
below 10 % ethanol in sterile physiological saline. [18F]flu-
mazenil showed ≥99 % radiochemical purity, specific acti-
vity of 264 ± 100 GBq/μmol (n = 3) at end of synthesis
(EOS), and a decay-corrected radiochemical yield of
34 ± 22 % (n = 3).
Animals
Male mice (FBV/NJ, 5–6 weeks old, n = 45, weight at
the time of scan 25 ± 2 g) were purchased from Jackson la-
boratories (Jax, Sacramento, CA). FBV/NJ male mice were
chosen to support future studies in juvenile transgenic
Fragile X KO FBV/NJ mice using [18F]flumazenil. All
animal experiments were approved by the Stanford
Administrative Panel on Laboratory Animal Care (APLAC)
who is accredited by the Association for the Assessment
and Accreditation of Laboratory Animal Care (AAALAC
International) and uphold all federal and state regulations
governing the humane care and use of laboratory animals.
Mice had free access to food and water and were allowed
ample time to acclimatize before the experiments. The
mice were randomly assigned to one of four groups
(isoflurane-treated, ketamine/dexmedetomidine (ket/dex)-
treated, dexmedetomidine-treated (dex), and awake) and
examined by a combination of PET and ex vivo proce-
dures as outlined in Fig. 2. The isoflurane and ket/dex
groups were subjected to a 60-min dynamic PET scan and
then dissected for ex vivo biodistribution measurements.
The dex and awake groups were scanned with PET
for 10 min under brief isoflurane anesthesia at 20–30
(midframe at 25 min) or at 50–60 (midframe at 55 min)
min post injection of [18F]flumazenil, followed by imme-
diate ex vivo dissection. Furthermore, additional mice in
the dex and awake groups were sacrificed for ex vivo
biodistribution measurements at 1, 5, 10, 15, 30 or 60 min
post injection of [18F]flumazenil. The drugs and respective
dosages used for anesthesia were based on the recom-
mended drug doses prescribed by IACUC—Institutional
Animal Care and Use, by the AALAS—American Associ-
ation of Laboratory Animals.
PET acquisition
On the day of the experiment, the mice were trans-
ported to the imaging facility at least 1 h prior to the
experiment. Animals were anesthetized one at a time
using either 2 % isoflurane inhalation (n = 4), the ket/dex
Fig. 2 Experimental design of PET imaging (n = 4 in each scanning)
and ex vivo (n = 4 at each time-point) procedures. A 10-min static
PET scanning was obtained under acute isoflurane anesthesia, after
an uptake phase while awake. Ket/Dex refers to a combined
ketamine/dexmedetomidine dex anesthesia. All PET scanning
groups were studied ex vivo at the end of the scan
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mixture (25 mg ket and 0.25 mg dex per mL sterile
physiological saline; 4 mL/kg by intraperitoneal (i.p.)
injection; n = 4), dex (0.25 mg/mL in sterile physiological
saline; 80–120 μL by i.p. injection), and the last group
was injected awake and without sustained anesthetic
treatment. A catheter was placed in a tail vein of the
fully sedated mice (isoflurane and ket/dex groups); in
addition, an i.p. catheter was placed in the ket/dex anes-
thetized mice in order to give supplemental injection of
1 μL/g of the anesthetic mixture at 40 min after the
initial dose. A bolus of 100 μL saline was injected in the
tail catheter to maintain patency of the catheter and to
hydrate the mouse. An ophthalmic lubricant was applied
to the eyes of the animals. Mice undergoing PET scans
were placed in a custom-made 4 × 4 mouse bed [39],
which was positioned within the aperture of the Siemens
Inveon microPET/CT. Isoflurane anesthetized and ket/
dex anesthetized mice were scanned on separate days.
The mice were kept warm during the scan using an
infrared lamp. A CT scan was performed, for attenuation
correction and anatomic registration, followed by a
60-min-long dynamic PET acquisition initiated upon
intravenous bolus injection of [18F]flumazenil (5.30 ±
0.33 MBq, n = 45, within 2 h from EOS). The awake
mice were placed in a tail-restraining device, and a glove
containing warm water was applied to the restrained tail,
which was then cleaned with 70% ethanol wipes. [18F]Flu-
mazenil was injected as a bolus though a tail vein, and the
animals were returned to their holding cage. At 25 or
55 min post tracer injection, the awake mice were briefly
anesthetized with 2% isoflurane in oxygen at 2 L/min. The
mice were positioned in the Siemens Inveon microPET/
CT as described above, whereupon a 10-min PET acqui-
sition was obtained, followed by a CT scan. At the conclu-
sion of the scans, mice were sacrificed and radioactivity
concentrations were measured in the brain, plasma, and
whole blood as described below, corresponding to 35 and
65 min post injection, respectively.
Ex vivo dissection
On the day of the experiment, the mice were trans-
ported to the imaging facility at least 1 h prior to the
experiment. One group of mice was administered dex
(1 mg/kg i.p.) as a single injection from a stock solution
of 0.25 mg/mL (80–120 μL) in physiological saline, the
other group received no pre-treatment. Each mouse was
injected with [18F]flumazenil (5.30 ± 0.33 MBq, n = 45,
within 2 h from EOS) while conscious and allowed to
return to their home cage. The mice were sacrificed by
cervical dislocation at times ranging from 1 to 60 min
post [18F]flumazenil injection. Trunk blood samples were
collected, and the brain was immediately removed from
the skull and dissected into frontal cortex, striatum,
hippocampus, brainstem, and cerebellum. A portion of
trunk blood was centrifuged to separate the plasma.
Radioactivity concentrations were measured in weighed
tissue samples, whole blood, and plasma using a Packard
Cobra II automated gamma counter, with correction to
radioactivity at the time of tracer injection relative to the
entire injected dose (%ID/g).
PET/CT reconstruction
CT images were recorded for the whole field of view,
using half rotation and 120 projections, 80 kV 500 μA
current, and a 255 ms exposure. The CT image was
reconstructed using a Feldman filtered back projection
with 2× down-sampling and 4 × 4 binning, giving an
effective pixel size of 103.2 μm. This structural image
was used for attenuation correction of the PET record-
ings, as well as colocalization with the structural MRI.
Decay events were recorded in list mode continuously
over the course of the scan (60 or 10 min) with an
energy window of 350–650 keV, and histogrammed into
1 × 10 min frames for static imaging or a series of 34
frames 12 × 10 s, 13 × 60 s, and 9 × 300 s) without
scatter correction or smoothing. The frames were then re-
constructed using four iterations of Fourier rebinning,
followed by an attenuation-weighted two-dimensional or-
dered-subsets expectation-maximization (AW-2DOSEM)
with a matrix size of 128 × 128 pixels.
MRI acquisition
One representative mouse was anesthetized with 2 %
isoflurane in oxygen at a flow rate of 2 L/min, and
scanned with a dedicated small animal 7.0 Tesla MR
scanner (Varian Magnex Scientific). The instrument was
equipped with a gradient insert with a bore size of 9 cm
(Resonance Research Inc, 770 mT/m, 2500 T/m/s), an
amplifier (Copley 266), and a console (General Electric
Medical Systems). Coronal two-dimensional images were
acquired from the brain of the mouse, using a spin echo
(SE) pulse sequence, echo time (TE) of 70 ms, repetition
time (TR) of 3000 ms, and a slice thickness of 500 μm.
The acquired data was reconstructed into a stack of 18
256 × 256 pixel images. The MRI images were used as
an anatomical guide for definition of the regions of
interest on the PET image.
Image analyses
PET/CT and MR images were imported into the Inveon
Research Workspace. PET data were co-registered
manually to the MR images using the CT images as an
anatomic guide. Brain regions of interest (ROI)—hippo-
campus and frontal cortex—were drawn on the MR
image and on the left ventricle of the heart using the
CT image and the first PET image frame. Time-activity
curves (TACs) were then extracted from each ROI and
calculated as %ID/g. The static PET images were summed
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from 20–30 and 50–60 min post tracer injection prior to
registration and extraction of the mean ROI activities.
Quantification of regional outcome measures via kinetic
analysis
There is no real reference region of [18F]flumazenil in
the mouse brain, and we therefore applied a more com-
plicated kinetic analysis using either an image-derived
input function or whole blood tracer concentration.
Mean [18F]flumazenil TACs in the two brain ROIs
(hippocampus and the frontal cortex) and the left
ventricle from the isoflurane and ket/dex groups were
calculated by averaging of the individual recordings.
For the ex vivo groups, the average [18F]flumazenil
TACs in the two brain ROIs and for whole blood were
obtained by averaging individually measured curves within
the group. A parametric model defined by a straight line
ascending to the initial peak followed by a tri-exponential
decay was fitted to the mean heart TACs and the average
whole blood curve. The image-derived blood curves were
not corrected for the metabolism of [18F]flumazenil
because multiple blood samples could not be performed
in same mice. The contribution of vascular radioactivity
to the regional brain target TACs was corrected prior to
analysis, assuming a 5 % blood volume. The corrected
target TACs in each dataset were then fitted using
one-tissue compartment (1TC) and two-tissue compart-
ment (2TC) models [40], with the fitted average heart
TAC serving as an image-derived input function for the
isoflurane and ket/dex groups, and the fitted average
whole blood curve for the ex vivo awake and dex groups.
Kinetic rate constants (K1 and k2 for 1TC and K1 to
k4 for 2TC) of the compartmental models were estimated
by nonlinear regression using MATLAB R2012b (Math-
works, Natick, MA, USA). Although TACs for both whole
blood and plasma were available for the ex vivo and dex
groups, the whole blood TAC was used as the input
function as it was considered to be more directly
comparable to the image-derived input function from
the dynamic PET scans. The heart ventricle image-derived
input function is commonly used for calculation of distri-
bution volume for tracers in small animals where sequen-
tial blood sampling is not possible and where binding in
myocardium is negligible [41, 42]. We denote here the
estimates of the [18F]flumazenil apparent total volume of
distribution (VT) obtained relative to the whole blood
input function (image-derived input function) as VT*, to
distinguish it from the (true) VT obtained from metabolite
corrected plasma concentration, as defined by Innis et al.
[43]. The measured activity concentration in whole blood
and plasma is similar so choosing the whole blood should
not give any bias on VT* calculations. As a measurement
of precision, standard errors were computed for each
estimated VT* value using a bootstrap algorithm [41] that
incorporates errors associated with fitting the input
function and the TAC for each target ROI.
Statistics
All values are given as value ± standard error of the
mean. Significant differences are calculated using an un-
paired two-sided t test unless otherwise noted, p values
less than 0.05 are considered statistically significant
and significance levels in graphs are marked as follows:
*p < 0.05, **p < 0.01, and ***p < 0.005.
Results
Static PET imaging under the four test conditions (Fig. 3)
clearly depicts the effects of anesthesia on [18F]fluma-
zenil binding to the GABAA receptors. At 25 min post
injection, the isoflurane anesthetized mice had uptake
exceeding 20 %ID/g in the high binding regions of
frontal cortex and hippocampus, compared with less than
2 %ID/g in the awake mice. The brain uptake in the ket/
dex and dex are of intermediate magnitude, with up
to 7 %ID/g in hippocampus and frontal cortex at 25 min.
This phenomenon was even more pronounced at 60 min
post injection, where the isoflurane anesthetized mice still
had brain concentrations close to 10%ID/g, whereas no
discernible [18F]flumazenil binding remained in brain of
the awake mice.
Brain TACs show that [18F]flumazenil uptake increases
over the first 10–12 min, to a maximum of 19.1 ± 0.5
%ID/g in the hippocampus and 14.6 ± 0.9%ID/g in the
frontal cortex in isoflurane-anesthetized mice (Fig. 4).
The high brain levels of [18F]flumazenil persisted through-
out the scan, with 11.4 ± 0.6 %ID/g in hippocampus and
9.3 ± 0.4 %ID/g in frontal cortex 60 min post injection.
The left heart ventricle activity peaked at 6.2 ± 0.1 %ID/g
very quickly after injection (~1 min post tracer injection)
and declined rapidly thereafter. This rapid decline suggests
that there is no specific binding in the myocardium.
[18F]flumazenil uptake in ket/dex anesthetized mice peaked
at 2 min post injection with 9.7 ± 1.3 %ID/g in hippocam-
pus, and at 5 min with 8.4 ± 0.9 %ID/g in frontal cortex,
whereas the heart signal peaked at 1 min with 7.9 ±
0.3 %ID/g and declined rapidly as in the isoflurane-
anesthetized mice. Dex treatment alone sedated, but
did not anesthetize the mice, such that dynamic PET
acquisition was not possible in this treatment group.
In the dex animals, [18F]flumazenil uptake peaked at
5 min post injection with 18.2 ± 6.9 %ID/g in the hippo-
campus, and at 17.5 ± 5.2%ID/g in frontal cortex, whereas
the whole blood concentration peaked at 1 min with
5.4 ± 0.1 %ID/g. The [18F]flumazenil uptake in awake
mice, as measured ex vivo, peaked at 1 min at 9.8 ±
2.4 %ID/g in the hippocampus and 10.5 ± 2.9 %ID/g
in the frontal cortex, and the whole blood content
also peaked at 1 min with 3.3 ± 0.8 %ID/g.
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The [18F]flumazenil uptake measured ex vivo (Fig. 5)
in hippocampus and frontal cortex was significantly
greater at 60 min post injection in all anesthetized con-
ditions compared with awake mice. The 2TC model con-
sistently provided better fits of the target TACs than did
the 1TC model. There was no statistically significant dif-
ference between the [18F]flumazenil VT* in the anesthe-
tized and dex-treated conditions in these brain regions
(frontal cortex p = 0.26, hippocampus p = 0.18). While
uptake in the ket/dex anesthetized mice was very similar
between the ex vivo and in vivo experiments, the uptake
under isoflurane anesthesia was much lower when mea-
sured ex vivo relative to the in vivo PET uptake derived
from the last frame 50–60 min post injection (frontal
cortex, isoflurane ex vivo 5.2 ± 0.5 % ID/g vs. in vivo 9.3
± 0.4 % ID/g, p < 0.001) (Fig. 5b). Furthermore, of all the
treatments, only isoflurane increased tracer uptake ex
vivo in the cerebellum compared with awake mice.
There was a similar trend towards an effect of isoflurane
on radioactivity concentration in whole blood and
plasma samples.
The apparent distribution volume relative to the heart
blood input (VT*) in the frontal cortex was unaffected
by isoflurane or dex relative to the awake group, as shown
in Fig. 6. However, combined ket/dex anesthesia did lower
the VT* in the frontal cortex significantly (p = 0.008).
However, VT* in the hippocampus was significantly in-
creased by isoflurane (p < 0.001) and dex alone (p = 0.002)
when compared to awake mice, whereas ketamine was
without effect. Furthermore, there was a highly significant
difference in VT* between the isoflurane condition and
the ket/dex condition (p < 0.001) in both frontal cortex
and hippocampus.
Discussion
The PET image data presented in Fig. 3 clearly depict
the effect of anesthetics on [18F]flumazenil uptake and
binding to GABAA sites in mouse brains: In the awake
condition, there was no discernible radioactivity in the
mouse brain at 60 min post injection, while all the
anesthetic conditions showed a persistent signal through-
out the brain. Isoflurane and other inhalation anesthetics
have long been known to perturb [18F]flumazenil distribu-
tion in the brain. Gyulai et al. [29] showed that isoflurane
globally increases uptake and binding of [11C]flumazenil
in human brain in a dose-dependent manner, as much as
doubling the distribution volume relative to the unanes-























































Fig. 3 Representative PET images overlaid a reference MR T1 structural image for localization of regions. Summed images from a dynamic scan
under isoflurane anesthesia (a) or ket/dex anesthesia (b) and static PET images from mice which have been injected awake then scanned under
brief isoflurane anesthesia, treated with dex alone (c), and previous awake animals (d). Note that the scale bars are different for a–d in order to
illustrate the full range of [18F]flumazenil binding





Fig. 4 Time-activity curves from the frontal cortex and hippocampus during different anesthesia conditions, isoflurane anesthesia (a, b), ket/dex
anesthesia (c, d) dex-treated awake mice (e, f), and awake (g, h). The gray circles represent the actual measured activity in the ROI, the red circles






















































































































Fig. 5 a Radioactivity concentrations in dissected brain regions and blood samples at 60 min post [18F]flumazenil injection, values are given as
the %ID/g in the region of interest. b Comparison of the radioactivity concentrations in sampled whole blood (ex vivo) vs. the image-derived
heart concentration from the PET scanner. Significant differences are reported relative to the awake condition
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that sevoflurane, an anesthetic from the same chemical
class as isoflurane, also increased the distribution volume
of [11C]flumazenil by 15–20 % in all regions except the
pons and white matter. In a test of a mixture of ketamine
and isoflurane anesthesia in rhesus monkeys, Sandiego et
al. [10] found a slight decrease in the [11C]flumazenil
binding potential, possibly due to opposing effects of the
two anesthetics. Our data with isoflurane alone support
these previous findings; we find an up to 94 % increase in
maximum uptake in hippocampus (19.1 % ID/g isoflurane
versus 9.8 % ID/g awake), corresponding to a 128 % in-
crease in VT* (6.4 mL/g isoflurane versus 2.8 mL/g
awake). The direct comparison between the PET-derived
data and ex vivo data is prone to bias induced by attenu-
ation correction and partial volume effects as well as
motion artifacts specifically in the ROI on the left ven-
tricle; all these effects suggest that the VT* from PET
might be overestimated compared with ex vivo measure-
ments. The comparison PET to ex vivo is further compli-
cated by administration of isoflurane in a chamber for the
ex vivo studies versus a head cone in the in vivo proced-
ure, resulting in slight dose differences. Nonetheless, we
do find the same trend when comparing the ex vivo con-
ditions at 60 min post injection; the [11C]flumazenil
concentration ex vivo in the hippocampus was 5.7 % ID/g
in the isoflurane condition versus only 0.048 % ID/g in the
awake condition. Despite this remarkable confounding
effect of anesthesia on [11C]flumazenil and [18F]flumazenil
binding, some preclinical PET imaging studies of GABAA
receptors are still published using isoflurane anesthesia.
The combination ket/dex has been the anesthesia of
choice in preclinical molecular imaging studies with flu-
mazenil based on the report by Salmi et al. [32], who did
not find any effect of subanesthetic doses of ketamine
on [11C]flumazenil binding in humans. However, to our
knowledge, this is the first such study to compare an
anesthetic dose of the commonly used mixture ket/dex
to the awake condition. We find that an anesthetic dose
of the ket/dex mixture does not alter the initial peak up-
take of [18F]flumazenil in the hippocampus (9.7 ± 1.3 %
ID/g in ket/dex and 9.8 ± 2.4% ID/g in awake). However,
it did significantly enhance the late retention of [18F]flu-
mazenil in hippocampus, which was 1.95 % ID/g at
60 min post injection, versus only 0.048% ID/g in the
awake condition. Dex alone did increase the initial up-
take of [18F]flumazenil in the hippocampus by up to
85 % (18.2 % ID/g dex and 9.8 % ID/g awake), and
had similar effects as the ket/dex mixture on tracer
retention as measured ex vivo 60 min post injection.
Interestingly, there was a 47 % decrease in the calculated
frontal cortex VT* for the ket/dex (2.33 ± 0.05 mL/g)
condition compared with awake animals (4.39 ± 1.06 mL/g)
but no difference in the hippocampus, while dex
alone increased VT* by 171% in the hippocampus
(7.60 ± 1.55 mL/g), compared with awake animals (2.77 ±
0.72 mL/g) but with no such effect in the frontal cortex.
The frontal cortical decrease in VT* with ket/dex
anesthesia supports the findings of Sandiego et al. [10],
who found a decrease in [11C]flumazenil binding potential
(BPND with the pons as reference region) in ketamine/
isoflurane-anesthetized Rhesus Monkeys. The higher
hippocampal uptake in mice with dex treatment supports
the findings of D’hulst et al. [19], who found a mild
(4.–6.0 %) increase in the binding of [18F]- or [11C]fluma-
zenil binding in dex-treated humans. This increase speci-
fically in the hippocampus VT* by dex alone could explain
why ket/dex did not decrease the VT* in both regions, as
the effects could have been counteracted by the dex
induced increase.
We observed a different response to the anesthetics
comparing the uptake and distribution volume in the
frontal cortex with the hippocampus. This could be
explained by the different site of action between
[18F]flumazenil and anesthetic and by the heterogenous
distribution of GABAA receptors subunits [44]. More than
20 different subunit combinations have been reported
[4, 45], among these, α1 subunits are widely distributed in
the cortex while α5 subunits are more pronounced in the
hippocampus [44]. In particularl, Momosaki et al. com-
pared the binding of [3H]flumazenil (RO15-1788) to that
of the structurally related [3H]Ro15-4513, which is more
α5 subunit selective than [3H]flumazenil [46], and found a
remarkable difference in the GABAA subtypes between
the cortex and hippocampus. Furthermore, the GABAer-
gic functionality is also different between cortical and
hippocampal regions, Whissell et al. found that while
the majority of cortical GABAergic neurons was parvalbu-
min (PV-expressing) positive, the hippocampal was chole-
cystokinin (CCK-expressing). While we cannot conclude































Fig. 6 The apparent volume of distribution (VT*; mL/g
−1) as
calculated using the two-tissue compartment model with an input
function but without metabolite correction. Significant differences
are relative to the awake condition
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study, we do find other evidence of regional differences in
GABAA receptor positive neurons.
There are several limitations to this study. Biases from
attenuation correction and partial volume effects can
hinder the direct comparison of PET data and ex vivo
data. We did see a difference in the whole blood radio-
activity of the isoflurane-anesthetized group when we
compare the ex vivo uptake values at 60 min with the
PET imaging-derived values; this difference might lead
to an underestimation of the true (VT*) and thus lower
the significance in our results. Our index of distribution
volume (VT*) is calculated using the whole blood radio-
activity instead of the plasma radioactivity as an input
function and is not corrected for plasma metabolites but
assumes that whole blood activity remains as untrans-
formed parent compound. The reported major meta-
bolites of [18F]- or [11C]flumazenil are known polar
compounds [47] and, as such, should not enter the brain.
However, differences in metabolite rates could affect the
radioactive concentration in blood and therefore is a
potential bias on the VT* calculations. The heart ventricle
image-derived input function serves for calculation of
distribution volume for tracers without substantial binding
in the myocardium and without important metabolism
during the scan [48, 49]. Finally, we calculated VT* on a
group basis rather than for individual mice, thus affording
a better comparison of PET scans and the ex vivo experi-
mental results.
We cannot rule out that some effects of anesthesia on
[18F]flumazenil uptake and binding arose from changes
in cardiac output, since central and peripheral GABAA
receptors do regulate heart rate [48], although cerebral
blood flow is the more salient issue, since it can influ-
ence delivery of lipophilic tracers to the brain. We argue
that the VT* index is a less biased measurement than
%ID/g in this regard, as it is a steady-state index. Further-
more, [18F]flumazenil is a substrate of the blood-brain
barrier efflux transporter P-glycoprotein [49], we cannot
rule out that anesthetics might have an actions on P-
glycoprotein function, further studies in P-glycoprotein
knockout animals would be needed.
Conclusions
We found that anesthesia or sedation with isoflurane, a
ketamine/dexmetomidine mixture, and dexmetomidine
alone all changed the pharmacokinetics of [18F]flumaze-
nil, consistently increasing tracer uptake, relative to non-
anesthetized condition (awake). Only the ketamine/
dexmetomidine mixture did not change the volume of
distribution (VT*) of [
18F]flumazenil in the hippocam-
pus, arguably due to opposing effects of the two agents
in combination. Results from this study emphasize the
importance of careful study design and control of the
experimental conditions when imaging GABAA receptors
under a condition of anesthesia. Any group differences in
[18F]flumazenil PET results need to be interpreted with
caution due to the potentially confounding effects of
anesthetic agents.
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